These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16288223)

  • 1. The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1.
    Abdul-Ghani R; Serra V; Györffy B; Jürchott K; Solf A; Dietel M; Schäfer R
    Oncogene; 2006 Mar; 25(12):1743-52. PubMed ID: 16288223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells.
    Wu D; Tao J; Xu B; Qing W; Li P; Lu Q; Zhang W
    Urol Int; 2011; 87(1):105-13. PubMed ID: 21597260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
    Imai Y; Yoshimori M; Fukuda K; Yamagishi H; Ueda Y
    Oncol Rep; 2012 Jun; 27(6):1703-9. PubMed ID: 22426819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
    Badinloo M; Esmaeili-Mahani S
    Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression.
    McDonald GT; Sullivan R; Paré GC; Graham CH
    Exp Cell Res; 2010 Nov; 316(19):3197-206. PubMed ID: 20736003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
    Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
    Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3'-kinase, in human colon cancer cells.
    Semba S; Itoh N; Ito M; Harada M; Yamakawa M
    Clin Cancer Res; 2002 Jun; 8(6):1957-63. PubMed ID: 12060641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
    Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
    Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells.
    Wu D; Tao J; Xu B; Qing W; Li P; Lu Q; Zhang W
    Urol Int; 2011; 86(3):346-54. PubMed ID: 21273759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines.
    Lee CM; Fuhrman CB; Planelles V; Peltier MR; Gaffney DK; Soisson AP; Dodson MK; Tolley HD; Green CL; Zempolich KA
    Clin Cancer Res; 2006 Jan; 12(1):250-6. PubMed ID: 16397049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
    Hu L; Hofmann J; Lu Y; Mills GB; Jaffe RB
    Cancer Res; 2002 Feb; 62(4):1087-92. PubMed ID: 11861387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Reversal effect of PI-3K/Akt pathway inhibitor LY294002 on multidrug resistance of ovarian cancer cell line A2780/Taxol].
    Shi XY; Cai XJ; Lei JX; Cao FJ; Pan DF; Chen P
    Ai Zheng; 2008 Apr; 27(4):343-7. PubMed ID: 18423117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GSK-3beta reactivation with LY294002 sensitizes hepatoma cells to chemotherapy-induced apoptosis.
    Beurel E; Kornprobst M; Blivet-Van Eggelpoël MJ; Cadoret A; Capeau J; Desbois-Mouthon C
    Int J Oncol; 2005 Jul; 27(1):215-22. PubMed ID: 15942663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
    Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
    Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway.
    Poh TW; Pervaiz S
    Cancer Res; 2005 Jul; 65(14):6264-74. PubMed ID: 16024628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002.
    Kunnimalaiyaan M; Ndiaye M; Chen H
    Surgery; 2006 Dec; 140(6):1009-14; discussion 1014-5. PubMed ID: 17188151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Connection of intracellular protein YB-1 localization in cell cultures of human tumors with multidrug resistance].
    Rybalkina EIu; Stromskaia TP; Ovchinnikov LP; Stavrovskaia AA
    Vopr Onkol; 2013; 59(5):623-8. PubMed ID: 24260892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of phosphatidylinositol 3'-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells.
    Uddin S; Hussain AR; Al-Hussein KA; Manogaran PS; Wickrema A; Gutierrez MI; Bhatia KG
    Clin Cancer Res; 2005 Apr; 11(8):3102-8. PubMed ID: 15837766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LY294,002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance.
    Barancík M; Bohácová V; Sedlák J; Sulová Z; Breier A
    Eur J Pharm Sci; 2006 Dec; 29(5):426-34. PubMed ID: 17010577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.